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A headspace-gas chromatography method for isopropanol 
determination in warfarin sodium products as a measure 
of drug crystallinity
Coumadin® and several generic products of warfarin so-
dium (WS) contain the crystalline form (clathrate) in which 
WS and isopropanol (IPA) are associated in a 2:1 molar ra-
tio. IPA is critical in maintaining the WS crystalline struc-
ture. Physicochemical properties of the drug and drug 
product may change when the crystalline drug transforms 
to amorphous form. A headspace-gas chromatography 
(HS-GC) method was developed and validated for IPA de-
termination in the WS drug product. n-propanol (NPA) was 
used as internal standard and the method was validated for 
specificity, system suitability, linearity, accuracy, precision, 
range, limits of detection and quantification, and robust-
ness. The method was specific, with good resolution be-
tween IPA and NPA peaks. Chromatographic parameters 
(retention time, IPA/NPA area ratio, tailing factor, theoreti-
cal plates, USP symmetry, capacity factor, selectivity and 
resolution) were consistent over three days of validation. 
The analytical method was linear from 2–200 µg mL–1 (0.1–
10 % IPA present in the drug product). LOD and LOQ were 
0.1 and 2 µg mL–1, respectively. Accuracy at low (2 µg mL–1) 
and high (200 µg mL–1) IPA concentrations of the calibration 
curve was 103.3–113.3 and 98.9–102.2 % of the nominal val-
ue, resp. The validated method was precise, as indicated by 
the RSD value of less than 2 % at three concentration levels 
of the calibration curve. The method reported here was uti-
lized to determine accurately and precisely the IPA content 
in in-house formulations and commercial products. In 
summary, IPA determination by HS-GC provides an indi-
rect measure of WS crystallinity in the drug product. Never-
theless, it should be confirmed by another analytical 
method since IPA from the drug substance is not distin-
guishable from IPA that may be present outside the drug 
crystals in a dosage form when prepared by wet granula-
tion with IPA.
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Narrow therapeutic index (NTI) drugs are those for which small differences in dose 
or concentration can lead to serious concentration-dependent therapeutic failures or ad-
verse drug events (1, 2). NTI drugs defined in the Code of Federal Regulations (3) are those 
drugs which exhibit less than a 2-fold difference in median lethal dose (LD50) and median 
effective dose (ED50) values, or have less than a 2-fold difference in the minimum toxic 
concentrations and minimum effective concentrations in the blood. These drugs are also 
called critical dose drugs, which often require therapeutic or pharmacodynamics monitor-
ing (4). Examples of NTI drugs are digoxin (5), warfarin sodium (WS) (6), carbamazepine 
(7), theophylline (8), phenytoin (9), etc. There are growing concerns regarding substitution 
of brand NTI drug products with generic ones due to safety and efficacy issues (9, 10). 
Concerns are further substantiated by recall data, which is significantly higher than that 
of overall drug products (2). For these reasons, some states in the USA do not allow substi-
tution of a brand NTI drug product with a generic one without prescriber consent (2, 11, 
12). Some regulatory agencies even tighten bioequivalence requirements for generic NTI 
products in order to increase confidence in the quality of such products, e.g., by tightening 
Cmax and AUC limit from 85–125 % to 90–111.11 % (2, 13). Furthermore, clinical performance 
of NTI drug products may be ensured by maintaining product quality throughout their 
shelf life and usage period.
WS is a NTI class drug (6) and is used to control hypercoagulable conditions such as 
venous thrombosis and its extension, pulmonary embolism, thromboembolic complica-
tions associated with atrial fibrillation and/or cardiac valve disease, recurrent myocardial 
infarction, and thromboembolic events such as stroke or systemic embolization after myo-
cardial infarction (14). WS commercial products contain its crystalline form. Crystalline 
WS is a clathrate molecule in which isopropanol (IPA) is a guest molecule trapped in the 
crystal lattice of WS. IPA provides stability to WS crystalline structure by interacting with 
oxygen atoms of the coumarin ring by hydrogen bonding and with sodium through a 
coordination bond. The crystalline structure would collapse without IPA (15). The US 
Pharmacopoeia (16) defined 2:1 molecular association between WS and IPA and its speci-
fication of 8.0–8.5 % in the drug substance. However, crystalline WS can convert to its 
amorphous form through loss of IPA. Amorphous and crystalline WS forms have distinct 
physicochemical properties. The change of crystalline to amorphous WS may influence 
product quality, e.g., hardness, disintegration time and dissolution rate and extent (17–21). 
IPA measurement provides an indirect method of measuring the crystallinity of the WS 
drug substance and its drug product since the amorphous form does not contain IPA. 
There is no literature report on a gas chromatography (GC) method for quantifying IPA in 
WS products. IPA is an important critical quality attribute of WS products as its presence 
or absence changes WS from the crystalline to amorphous form or vice versa. Thus, it as-
sures the optimal therapeutic performance of the product by influencing its bioavailabil-
ity. For example, an increase in hardness and disintegration time may result in a decrease 
in dissolution and bioavailability, and hence affect clinical performance (17, 18). The US 
Pharmacopoeia (16) IPA quantification method is intended for the drug substance not for 
the products and it uses the older packed column technology with liquid injection. This 
paper provides a validated headspace gas chromatography (HS-GC) method using a capil-
lary column for determination of IPA in commercial products. Such a method would allow 
sponsors to better monitor the quality of WS products during manufacture and through-
out their life cycle. The advantages of capillary columns vs. packed ones are well known. 
These include higher separation efficiency and sensitivity (22, 23). In addition, headspace 
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analysis provides cleaner injected samples with higher sensitivity to volatile compounds 
compared to liquid injection (24). Moreover, our group has already reported on crystallin-
ity determination of WS in pharmaceutical products using X-ray powder diffraction, near 
infrared, infrared, Raman and solid-state nuclear magnetic resonance spectroscopy (19–
21). None of these methods directly measure IPA, which further provides assurance of WS 
crystallinity in the product.
EXPERIMENTAL
Materials
Crystalline WS clathrate (Ark Pharma Inc., USA), HPLC grade IPA, dimethylsulfoxide 
(DMSO) (Fisher Scientific, USA), ACS grade n-propanol (NPA) (J. T. Baker, USA), lactose 
monohydrate (LM), anhydrous lactose (LA) (Foremost Farms, USA), pregelatinized starch 
(Starch 1500®, Colorcon, USA), magnesium stearate (MgSt), hydroxypropyl cellulose (HPC) 
(MW 80K, Sigma-Aldrich, USA) were used as received. 18 MW deionized water was ob-
tained from an in-house Milli-Q Gradient A-10 water purification system (Millipore, USA).
Headspace-gas chromatography operating conditions
IPA content in the formulations was determined by the HS-GC method. The head-
space sampler was a pressure-loop HT3 model (Teledyne Tekmar, USA). The HS parame-
ters used were: GC cycle time 19.25 min, valve oven temperature 105 oC, transfer line 
temperature 110 oC, platen temperature 80 oC, platen temperature equilibration time 0.5 
min, sample equilibration time 25 min, vial pressure 204.7 kPa, pressurization time 1 min, 
pressure equilibration time 0.5 min, loop fill pressure 170.3 kPa, loop fill time 1 min and 
inject time 1 min.
The GC system used was a 7890 model (Agilent Technologies, USA), equipped with 
split/splitless injector (8:1 split ratio, 150 °C) and a flame ionization detector maintained at 
300 oC, with gas flows of 450 mL min–1 air, 50 mL min–1 hydrogen and 25 mL min–1 helium 
makeup. The capillary column used was a 30 m × 0.32 mm × 1.8 µm Rxi®-624Sil MS (Restek 
Corporation, USA). Column initial temperature was 50 oC maintained for 3.5 min, then 
ramped to 120 oC at 40 oC min–1 and kept for 6 min. Helium was used as a carrier gas flow-
ing at a rate of 5.695 mL min–1.
Preparation of isopropanol solutions
Two stock solutions of 20 mg mL–1 IPA were prepared by weighing accurately 1 g IPA 
in a volumetric flask and making up the volume to 50 mL with water. One stock solution 
was used for calibration and the other for accuracy (quality control) samples. Standard 
solutions of 10, 7.5, 5, 2.5, 1, 0.5, 0.25 and 0.1 mg mL–1 were used for calibration. Separately, 
another set of solutions of 10, 5 and 0.1 mg mL–1 were used for accuracy evaluation.
Similarly, the internal standard (IS) solution (5 mg mL–1) was prepared by weighing 
125 mg NPA into a 25-mL volumetric flask and making up the volume with water. Calibration 
(2–200 µg mL–1), quality control (2, 100 and 200 µg mL–1) and system suitability (20 µg mL–1) 
samples were prepared by adding 4.8 mL water, 100 µL IS and 100 µL of standard IPA solu-
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tion into vials and vortexing for 15 s. Concentrations of calibration samples were 2, 5, 10, 
20, 50, 100, 150 and 200 µg mL–1 (0.1–10 % IPA present in the drug product). The 20 µg mL–1 
IPA solution was used for the system suitability test; 2, 100 and 200 µg mL–1 concentrations 
were used for accuracy testing.
Preparation of in-house formulations
Two WS tablet formulations (dose: 10 mg) were manufactured by direct compression. 
The excipients chosen were based on excipients used in the commercial WS tablets. The 
formulation composition was as follows: 5 % WS (crystalline form), 86 % LM (product LM) 
or LA (product LA), 5 % pregelatinized starch, 2.5 % HPC and 1 % MgSt. All formulation 
components (except MgSt) were passed through a 0.425 mm sieve and blended in a MINI-
BLEND™ (Globe Pharma, USA) for 15 min at 10 rpm. MgSt was passed through a 0.250 mm 
sieve, added to the formulation blend and mixed for another 5 min in the blender. Final 
blends were compressed into tablets using a Mini Press-1 (Globe Pharma, USA) 10-station 
tableting machine with 8-mm flat die and punches (Natoli Engineering Company, USA). 
Placebo formulations were prepared in the same way.
Sample preparation
Sample preparation involved addition of one formulation tablet into a vial containing 
4.9 mL water and 100 µL IS. Contents were placed on a horizontal shaker for 60 min at 120 
rpm and vortexed for 1 min before being placed in the HS-GC autosampler. Similarly, the 
IPA content in three commercial products was also determined to show the potential use 
of the validated method. Three commercial products of 5 mg strength were purchased 
from a local pharmacy and coded as product A, B and C (commercial products). HS-GC 
samples of commercial products were prepared in the same way as those of in-house for-
mulations, except that two tablets were used in sample preparation instead of one tablet. 
This was due to the half potency of commercial products (5 mg WS) in comparison with 
the in-house formulations (10 mg WS).
Method validation
The method was validated for specificity, system suitability, linearity, accuracy, preci-
sion (repeatability and intermediate precision), linearity range, limits of quantification and 
detection (LOQ and LOD) and robustness, to demonstrate the suitability of the method as 
per ICH and USP guidance documents (16, 25).
Specificity. – Specificity was checked by injecting a blank (water), internal standard 
(NPA), analyte (IPA) and a sample containing both. In addition, placebo and WS formula-
tions which contained excipients were tested. All chromatograms were analyzed for inter-
ferences in the region where IPA and NPA peaks would elute.
Linearity. – Linearity of the method was evaluated by running calibration standard 
solutions in duplicate in an eight-concentration range for three days. The concentration 
ranged from 2–200 µg mL–1 of IPA present in the drug product (10 mg warfarin sodium). 
Regression analysis using the least squares method was performed on IPA/NPA area ratios 
and IPA concentrations. Linearity was evaluated by the following parameters of the re-
35
Z. Rahman et al.: A headspace-gas chromatography method for isopropanol determination in warfarin sodium products as a measure 
of drug crystallinity, Acta Pharm. 68 (2018) 31–46.
 
gression line: correlation coefficient, slope and its intercept, 95 % confidence interval of the 
intercept, residual sum of the squares and the residual plot. Slope fluctuations are indica-
tive of the method inaccuracy. The slope of the developed line was consistent in inter-day 
analysis and varied from 0.99 × 10–2 to 1.01 × 10–2 mL µg–1.
Accuracy. – Accuracy was determined with IPA standards at three concentrations, 
namely, 2, 100 and 200 µg mL–1, which represented low, medium and high IPA concentra-
tions in the calibration curve. Five replicate sample injections of each concentration were 
injected and IPA was calculated.
Accuracy was also determined in the drug products in an attempt to account for the 
influence of formulation on the estimation of IPA. The method of standard additions was 
used (26). Commercial product samples containing one tablet were spiked with 100 µL of 
100 µg mL–1 IPA standard and 100 µL IS in 4.8 mL water.
Precision. – Precision of the method was established as repeatability and intermediate 
precision. Repeatability was performed by injecting five samples of 2, 100 and 200 µg mL–1 
solution containing IS. Intermediate precision was determined by comparing RSD on dif-
ferent days. Precision of in-house and commercial products analysis was also determined 
by injecting three samples.
Limit of quantification and limit of detection. – LOQ was the lowest concentration of ana-
lyte within the linearity range that could be determined with acceptable accuracy and 



























































































GC factor DOE-1 47.5 5.410 157.5 84 23.75 96.5
Colum temperature (oC) 47.5 50.0 52.5 DOE-2 50.0 5.695 150.0 80 25.00 103.4
Carrier gas flow (mL min–1) 5.410 5.695 5.980 DOE-3 52.5 5.410 157.5 76 23.75 110.3
DOE-4 47.5 5.980 157.5 76 26.25 96.5
Injector temperature (oC) 142.5 150.0 157.5 DOE-5 52.5 5.410 142.5 84 26.25 96.5
DOE-6 52.5 5.980 157.5 84 26.25 110.3
HS factor DOE-7 47.5 5.410 142.5 76 26.25 110.3
Platen temperature (oC) 76 80 84 DOE-8 52.5 5.980 142.5 76 23.75 96.5
Equilibrium time (min) 23.75 25 26.25 DOE-9 50.0 5.695 150.0 80 25.00 103.4
DOE-10 50.0 5.695 150.0 80 25.00 103.4
Vial pressure (kPa) 96.5 103.4 110.3 DOE-11 47.5 5.980 142.5 84 23.75 110.3
DOE – design of experiment, GC – gas chromatography, HS – headspace
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precision under the stated conditions. A signal-to-noise ratio (S/N) of 10:1 can also provide 
an estimate of LOQ. LOD was calculated from S/N of at least 3:1 (16, 25).
Robustness. – Method robustness was studied by the design of experiment method 
(DOE) (27). Six independent variables of GC and HS were selected based on the literature 
and instrument parameters. The independent GC variables studied were: column tem-
perature, carrier gas flow and injector temperature. Independent variables selected for HS 
were platen temperature, equilibration time and vial pressure. Upper and lower values of 
variables were 95 and 105 % of the center value (optimized), resp. A fractional factorial 
DOE was run with 11 experiments that contained a triplicate center point (three-day vali-
dation) (Table I). The selected parameters were: retention time (tR), IPA/NPA area ratio, 
peak width, tailing factor, peak symmetry, number of theoretical plates, selectivity, resolu-
tion and IPA content in the in-house formulations.
System suitability. – The purpose of the system suitability test was to confirm that 
critical chromatographic parameters were adequate for analyses. System suitability was 
determined by running six injections of a sample containing 20 µg mL–1 IPA before other 




Headspace-gas chromatography. – Initially, liquid injection with a capillary GC column 
was used. Eventual loss of precision in system suitability samples was observed. This was 
likely due to non-volatile components in the samples accumulating in the injection liner 
and front of the column. This required frequent liner changes and column cutting to re-
cover precision to acceptable levels. In addition, the range of liquid injection did not go 
below 20 µg mL–1 IPA. Switching to the headspace technique greatly reduced the need for 
liner changes and column cutting. Furthermore, headspace analysis lowered the LOQ by 
at least one order of magnitude, i.e., 2 µg mL–1 IPA.
Sample preparation. – Samples were shaken on a mechanical shaker because the results 
for IPA for these samples reached higher precision compared to sonicated samples. Water 
was selected as the diluent because it provided cleaner chromatograms compared to 
DMSO. Water samples also had peak areas approximately twice as large for IPA and three 
times for NPA. This might be due to the lower miscibility of IPA and NPA with water 
compared to DMSO. A salt was added to the water to further lower the solubility of ana-
lytes (IPA and NPA). Use of sodium sulfate resulted in an increase in IPA and NPA peak 
areas of up to 2.5–3 times. In addition, crimp top headspace vials yielded slightly larger 
chromatographic peaks compared to screw caps. This was presumably due to the crimp 
cap vials having a tighter seal. However, the method already provided the necessary sen-
sitivity. For method simplicity, a salt was not added and screw cap vials were employed 
because of their ease of use. Crushing the tablets or heating the samples while shaking did 
not result in increased recovery of IPA.
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Method validation
Specificity. – Blank samples did not show any peaks while NPA and IPA showed peaks 
at distinguished tR. Baseline resolution of IPA and NPA peaks could be achieved when 
chromatographic resolution (Rs) was equal or greater than 1.5. IPA and NPA were well 
separated and eluted at 1.4 and 2.0 min, resp.; chromatographic resolution was higher than 
9.20 (Fig. 1). Placebo and WS formulations containing either LM or LA as a major compo-
nent did not show interfering peaks in the region of 1.2 to 2.5 min, which was the region 
of IPA and NPA peaks (Fig. 2).
System suitability. – The method met system suitability parameter requirements as 
outlined in FDA and US Pharmacopeia documents (16, 31). Variability in the IPA/NPA area 
ratio was very low, as indicated by the RSD value of less than 0.1 %. Tailing factor was less 
than 1.12, USP symmetry was between 0.85 and 0.92 and theoretical plates were more than 
9266 and 14003 for IPA and NPA peaks, resp. Selectivity (α) between two peaks was 1.81 
and chromatographic resolution between the peaks was more than 9.20. The suitability 
parameters data were consistent in inter-day validation (Table II).
Linearity. – The correlation coefficient between the IPA/NPA area ratio and the chosen 
concentration range was 0.9999, which indicated a very good linear correlation between 
Fig. 1. Chromatograms of: a) water, b) n-propanol, c) isopropanol and d) n-propanol + isopropanol.
a)                                                                            b)
c)                                                                            d)
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two variables (Table III, Fig. 3a). The regression model predicted values were very close to 
the actual values and the residuals between the actual and model predicted values were 
very low (Fig. 3b). Fitness of the regression model was further determined by the residual 
sum of the squares (RSS), which measures the discrepancy between the actual and model 
estimated values. Lower RSS values indicated good fit of the model to the data. In addition, 
the intercept was very low, indicating a low constant error in the model.
Range. – The results of the studies indicated that the linearity range of the calibration 
curve was from 2 to 200 µg mL–1 (Table III).
Accuracy and matrix effect. – Accuracy data is shown in Table III. Accuracy of the method 
was measured through IPA solutions at three concentrations (2, 100 and 200 µg mL–1; 
LOQ, medium and high level of linearity range). It varied from 103.3–113.3, 98.6–101.0 and 
98.9–102.2 % of the nominal values, resp., in three-day validation studies. In addition, the 
effects of excipients on IPA results were indirectly estimated since no placebo tablets of 
commercial products are available. Samples containing one commercial product tablet, IS 
and IPA solution (100 µg mL–1) were tested for the matrix effect of the formulation. The 
results of analyte spike indicated that the matrix had no effects on IPA values. Measured 
recovery of the added IPA was within 2 % of the nominal amount added (Fig. 4). 
Fig. 2. Chromatograms of formulations: a) product LM placebo, b) product LA placebo, c) product LM, 
d) product LA. LA, LM – in-house formulations.
a)                                                                           b)
c)                                                                           d)
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Precision. – The RSD of repeatability measurements of the samples of 2, 100 and 200 µg 
mL–1 concentrations were 1. 9, 1.1 and 1.4 %, resp. Similarly, intermediate precision RSD of 
the same samples on different days was in the range of 0.4–1. 9, 0.9–1.6 and 0.8–1.4 %, resp. 
(Table III).
LOQ and LOD. – 2 µg mL–1 was chosen as LOQ based on its acceptable linearity, ac-
curacy and precision (Table III). S/N was 100 at this concentration, which was an order of 
Table II. Chromatographic parameter/system suitability data of HS-GC methoda
Parameter
IPA peak NPA peak IPA peak NPA peak IPA peak NPA peak
Day 1 Day 2 Day 3
Retention time (min) 1.43 ± 0.11 2.01 ± 0.09 1.43 ± 0.11 2.01 ± 0.07 1.43 ± 0.12 2.01 ± 0.07
Tailing factor 1.12 ± 0.76 1.07 ± 0.27 1.12 ± 0.87 1.07 ± 0.97 1.12 ± 0.54 1.08 ± 0.50
USP symmetry 0.86 ± 0.95 0.92 ± 0.44 0.85 ± 1.66 0.92 ± 1.34 0.85 ± 1.22 0.91 ± 1.28











HETP (mean, mm) 3.19 2.11 3.24 2.14 3.21 2.13
Capacity factor, k’ 1.03 ± 0.18 1.87 ± 0.00 1.03 ± 0.17 1.87 ± 0.00 1.03 ± 0.20 1.87 ± 0.00
Selectivity (α) 1.81 ± 0.00 1.81 ± 0.00 1.81 ± 0.00
Chromatographic 
resolution (Rs)
9.27 ± 1.06 9.20 ± 1.15 9.23 ± 1.22
IPA/NPA area ratiob 0.20 ± 0.20 0.20 ± 0.63 0.20 ± 0.55
IPA – isopropanol, NPA – n-propanol
a Mean ± RSD, n = 6.
b IPA: 20 mg mL–1; NPA: 100 mg mL–1
Fig. 3. a) Calibration curves and b) residual plots of actual and predicted values of isopropanol (IPA).
a)                                                                              b)
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magnitude above the typical S/N requirement of 10 for LOQ. LOD was found to be 0.1 µg 
mL–1 with a S/N of 5.
Robustness. – Robustness results are shown in Fig. 5 and Table IV. The tR, peak width, 
tailing factor and theoretical plates for IPA and NPA ranged between 1.33 and 1.54 min, 
Table III. Validation results 
Parameter Day 1 Day 2 Day 3 Mean/mean ± SD
Linearitya
Correlation coefficient 0.9999 0.9999 0.9999 0.9999
Slope (µg mL–1) 0.99 × 10–2 1.01 × 10–2 1.01 × 10–2 1.00 × 10
–2 ± 
0.15 × 10–3 a,c
Y-intercept –0.13 × 10–2 –0.07 × 10–2 –0.23 × 10–2 –0.14 × 10
–2 ± 
0.08 × 10–2 a,c
Y-intercept confidence interval –0.34 × 10
–2 to 
–0.10 × 10–2
–0.18 × 10–2 to 
0.03 × 10–2
–0.26 × 10–2 to 
–0.20 × 10–2
–0.36 × 10–2 to 
0.02 × 10–2
Residual sum of squares 2.79 30.46 51.77 27.28 ± 24.56a,c
Concentration range (µg mL–1) 2–200 2–200 2–200 2–200
LOD (µg mL–1)a 0.1 0.1 0.1 0.1
LOQ (µg mL–1)a 2 2 2 2
Accuracy, mean (%)
2 µg mL–1 b 111.0 103.3 113.3 109.2
100 µg mL–1 b 101.0 98.6 100.3 100.0
200 µg mL–1 b 102.2 98.9 100.8 100.6
Product A + 100 µg mL–1 IPA spikea 101.9 – – 101.9 
Product B + 100 µg mL–1 IPA spikea 101.1 – – 101.1 
Product C + 100 µg mL–1 IPA spikea 101.80 – – 101.8
Precision, RSD (%)
2 µg mL–1 b 1. 9 0.9 0.4 1.1
100 µg mL–1 b 1.1 1.6 0.9 1.2
200 µg mL–1 b 1.4 0.8 1.0 1.0
Product LMa 1.9 1.7 2.4 2.0
Product LAa 0.4 1.3 0.1 0.6
Product Aa 0.8 – – 0.8
Product Ba 0.6 – – 0.6
LOD – limit of detection, LOQ – limit of quantitation, A, B, C – commercial formulations, IPA – isopropanol, LA, 
LM – in house formulations
a n = 3, b n = 5, c mean ± SD
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0.0344–0.0386 min, 1.10–1.25 and 8352–9978, and 1.84–2.22 min, 0.0382–0.0439 min, 1.04–
1.10 and 12182–15367, resp. In addition, resolution between IPA and NPA peaks ranged 
from 8.24–10.04. Column temperature had a statistically significant (p < 0.05) effect on all 
chromatographic parameters (tR, tailing factor, theoretical plates, resolution). The tR, sym-
metry and tailing factor of IPA and NPA were significantly (p < 0.05) affected by the car-
rier gas flow rate, but the IPA/NPA area ratio was not affected by the studied variables (Fig. 
5). Similarly, the result for IPA content in in-house formulations was not significantly af-
fected by the selected HS-GC independent variables (Table III). Since the measurement of 
IPA was not affected, the method can be considered robust. However, it should be noted 
that column temperature and flow rate should be strictly controlled to maintain system 
suitability.
Linearity was not affected by the independent factors studied, as indicated by the cor-
relation coefficient > 0.9995 between the IPA/NPA area ratio and actual IPA content and 
negligible intercept (Table IV). Furthermore, the predicted models and actual IPA values 
were in good agreement, as indicated by R2-predicted > 0.942 for all the studied responses. 
R2-adjusted and R2-predicted were in reasonable agreement, as indicated by the difference 
of less than 0.2. Furthermore, ANOVA analysis of the data indicated that tR, peak width, 
tailing factor, theoretical plates and resolution were significantly (p < 0.05) affected by the 
studied variables for NPA (Table IV). IPA showed the same trend (p < 0.05), except for the 
tailing factor.
Analytical application
Accuracy and precision of the validated method were evaluated by measuring the IPA 
content in a known sample (quality control samples). Accuracy was found to be very close 
Fig. 4. Chromatograms of: a) product A, b) product A + 100 µg mL–1 IPA, c) product B, d) product B + 100 
µg mL–1 IPA, e) product C and f) product C + 100 µg mL–1 IPA. A, B, C – commercial formulations, IPA 
– isopropanol.
a)                                                         b)                                                         c)
 
d)                                                         e)                                                         f)
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to the actual values, with high precision indicated by low RSD values (Table III). Applica-
tion of the validated method was further tested in in-house and commercial formulations 
and calculation for WS crystallinity was based on the 2:1 molecular mass ratio between WS 
and IPA. IPA contents of in-house formulation products LM and LA were 158.73 ± 1.97 µg 
mL–1 (7.94 ± 1.97 % IPA or WS crystallinity 95.18 ± 1.97 %) and 155.87 ± 0.60 µg mL–1 (7.79 ± 
0.60 % IPA or WS crystallinity 93.46 ± 0.60 %) (average of three days) (formulations DOE-2, 
DOE-9 and DOE-10, Table IV), respectively. The results were accurate, as indicated by 
three-day values. Similarly, IPA contents in commercial products A, B and C were 79.00 ± 
0.76 µg mL–1 (3.95 ± 0.76 % IPA or WS crystallinity 47.37 ± 0.76 %), 97.40 ± 0.76 µg mL–1 (4.87 
± 0.62 % IPA or crystallinity 58.40 ± 0.62 %) and below LOQ (1.2 µg mL–1), resp. The RSD of 
in-house LM and LA formulations varied from 0.5 to 2.4 % and 0.1 to 2.5 %, resp. Similarly, 
RSD varied from 0.6 to 0.8 % for commercial formulations. Thus, the method was precise, 
as indicated by low RSD values (Table III and IV).
The IPA and crystallinity values of the commercial products were low compared to 
the in-house products probably due to the use of unsealed bottles that were purchased six 
months before testing. Furthermore, there were variations in IPA contents among the 
products, which may be due to the differences in composition or manufacturing method, 
Fig. 5. Robustness of: a) retention time (min), symmetry and tailing factor of IPA peak, b) retention 
time (min), symmetry and tailing factor of NPA peak, c) theoretical plates of IPA and NPA, d) selectiv-
ity (a) and resolution factor. IPA – isopropanol, NPA – n-propanol.
a)                                                                                       b)
 
c)                                                                                       d)
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since product A, product B and product C were manufactured by dry granulation, direct 
compression and wet granulation, resp. In conclusion, the developed method can be used 
to determine IPA in warfarin sodium products as no literature or pharmacopeial method 
for this purpose is available.
CONCLUSIONS
Measuring IPA in the WS product provides an indirect means of measuring drug 
crystallinity in the product. Validated HS-GC method provides a reasonably fast and ac-
curate method to monitor IPA. However, the results for IPA obtained by HS-GC may not 
distinguish between IPA of the drug substance and that of the excipients present in the 
formulation. It needs to be confirmed by a secondary method, which may be spectroscopy 
or X-ray powder diffraction, as indicated in our previous works (19–21).
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